MOSCOW (MRC) -- Melitek, the Danish medical compound specialist, has announced an expansion of its plant including a new production line, according to GV.
The company broke ground on the plant in Nr. Alslev in September 2013 and expects to be in full operation by September 2014 with an additional nominal production capacity of up to 8,000 tons. The new production facility will provide Melitek with about 1,200 square meters of additional space including a new production line.
The Danish company said that it has experienced a steady growth in demand for its Meliflex compounds customised for pharmaceutical packaging and medical devices.
"We have chosen to make a significant investment for the future of our company in order to service coming needs of our customers and to allow for growth into emerging markets", comments Kim Laursen, Managing Director. He continues, "We are privileged to supply leading healthcare companies and their key converters, hence our investment will guarantee higher flexibility and supply security for our customers which both are eminent for medical companies".
As MRC reported earlier, the value of the global medical polymer market is set to rise by more than half in the next five years, boosted by an ageing population and developing markets. The market is estimated to grow from USUSD2.3 bln to over USUSD3.5 bln, a rise of more than 52%, between now and 2018.
Melitek is a private owned Danish company specialised in medical compounds based on 30 years of experience servicing the healthcare market. Under the brand name Meliflex the company offers a broad range of materials (PE, PP, TPE, TPO and COC based compounds) that are produced according to GMP and ISO with an extensive medical service package. The compounds are PVC-free and do not contain any phthalate plasticizers.
MRC